Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1974 1
1983 1
1985 1
1986 3
1987 1
1988 1
1989 1
1990 1
1991 1
1992 3
1993 3
1994 1
1995 1
1997 1
1998 1
1999 1
2000 1
2003 1
2004 1
2008 1
2009 2
2010 1
2011 2
2012 5
2013 3
2014 2
2015 1
2016 4
2017 5
2018 1
2020 5
2021 7
2022 2
2023 4
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean g lignani[Author] (12 results)?
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Gounder M, et al. Among authors: grignani g. N Engl J Med. 2023 Mar 9;388(10):898-912. doi: 10.1056/NEJMoa2210140. N Engl J Med. 2023. Update in: Future Oncol. 2025 Apr;21(8):889-901. doi: 10.1080/14796694.2025.2462519. PMID: 36884323 Free PMC article. Updated. Clinical Trial.
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group.
Palassini E, Baldi GG, Sulfaro S, Barisella M, Bianchi G, Campanacci D, Fiore M, Gambarotti M, Gennaro M, Morosi C, Navarria F, Palmerini E, Sangalli C, Sbaraglia M, Trama A, Asaftei S, Badalamenti G, Bertulli R, Bertuzzi AF, Biagini R, Bonadonna A, Brunello A, Callegaro D, Cananzi F, Cianchetti M, Collini P, Comandini D, Curcio A, D'Ambrosio L, De Pas T, Dei Tos AP, Ferraresi V, Ferrari A, Franchi A, Frezza AM, Fumagalli E, Ghilli M, Greto D, Grignani G, Guida M, Ibrahim T, Krengli M, Luksch R, Marrari A, Mastore M, Merlini A, Milano GM, Navarria P, Pantaleo MA, Parafioriti A, Pellegrini I, Pennacchioli E, Rastrelli M, Setola E, Tafuto S, Turano S, Valeri S, Vincenzi B, Vitolo V, Ivanescu A, Paloschi F, Casali PG, Gronchi A, Stacchiotti S. Palassini E, et al. Among authors: grignani g. Cancer Treat Rev. 2024 May;126:102722. doi: 10.1016/j.ctrv.2024.102722. Epub 2024 Mar 30. Cancer Treat Rev. 2024. PMID: 38604052 Free article.
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. Among authors: grignani g. Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Lancet Oncol. 2017. PMID: 28499583 Clinical Trial.
Patients were randomly assigned (1:1) to receive three cycles of full-dose standard chemotherapy (epirubicin 60 mg/m(2) per day [short infusion, days 1 and 2] plus ifosfamide 3 g/m(2) per day [days 1, 2, and 3], repeated every 21 days) or histotype-tailored chemotherapy: f …
Patients were randomly assigned (1:1) to receive three cycles of full-dose standard chemotherapy (epirubicin 60 mg/m(2) per day [short infus …
Next generation immune-checkpoints for cancer therapy.
Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D. Donini C, et al. Among authors: grignani g. J Thorac Dis. 2018 May;10(Suppl 13):S1581-S1601. doi: 10.21037/jtd.2018.02.79. J Thorac Dis. 2018. PMID: 29951308 Free PMC article. Review.
New immune-checkpoints, with either stimulatory or inhibitory functions are emerging with key roles in regulating T cell response but also affecting other crucial effectors belonging to the innate immune response (e.g., natural killer). Their therapeutic exploitation, eith …
New immune-checkpoints, with either stimulatory or inhibitory functions are emerging with key roles in regulating T cell response but also a …
Evaluation of a New DNA Extraction Method on Challenging Bone Samples Recovered from a WWII Mass Grave.
Di Stefano B, Zupanič Pajnič I, Concato M, Bertoglio B, Calvano MG, Sorçaburu Ciglieri S, Bosetti A, Grignani P, Addoum Y, Vetrini R, Introna F, Bonin S, Previderè C, Fattorini P. Di Stefano B, et al. Among authors: grignani p. Genes (Basel). 2024 May 23;15(6):672. doi: 10.3390/genes15060672. Genes (Basel). 2024. PMID: 38927608 Free PMC article.
In this paper, a protocol based on the processing of 0.5 g of bone powder decalcified using Na(2)EDTA proved to be suitable for a semi-automated DNA extraction workflow using the Maxwell() FSC DNA IQ Casework Kit (Promega, Madison, WI, USA). ...
In this paper, a protocol based on the processing of 0.5 g of bone powder decalcified using Na(2)EDTA proved to be suitable for a sem …
Methylglyoxal-induced neurotoxic effects in primary neuronal-like cells transdifferentiated from human mesenchymal stem cells: Impact of low concentrations.
Coccini T, Schicchi A, Locatelli CA, Caloni F, Negri S, Grignani E, De Simone U. Coccini T, et al. Among authors: grignani e. J Appl Toxicol. 2023 Dec;43(12):1819-1839. doi: 10.1002/jat.4515. Epub 2023 Jul 10. J Appl Toxicol. 2023. PMID: 37431083 Free article.
Substantially, most effects occurred as low as 10 muM, concentration much lower than that reported from previous observations using different in vitro cell-based models (e.g., human neuroblastoma cell lines, primary animal cells, and human iPSCs). Remarkably, this low effe …
Substantially, most effects occurred as low as 10 muM, concentration much lower than that reported from previous observations using differen …
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.
Mesiano G, Zini R, Montagner G, Bianchi N, Manfredini R, Chillemi A, Aglietta M, Grignani G, Lampronti I, Fiorino E, Malavasi F, Sangiolo D, Gambari R, Ferrari D. Mesiano G, et al. Among authors: grignani g. Mol Med. 2017 Oct;23:235-246. doi: 10.2119/molmed.2017.00084. Epub 2017 Aug 9. Mol Med. 2017. PMID: 28805233 Free PMC article.
Mature CIK cells (day 21) produce a great variety of interleukins and secreted proteins that can be divided into 3 groups based on their secretion quantity: high (IL-13, RANTES, MIP-1alpha and 1beta), medium (IL-1Ra, IL-5, IL-8, IL-10, IL-17, IP-10, INF-gamma, VEGF and GMCSF) and …
Mature CIK cells (day 21) produce a great variety of interleukins and secreted proteins that can be divided into 3 groups based on their sec …
71 results